The nurse is instructing fatigue management to the client who is taking radiation.
The education should include information about?

Choice A rationale

Weight loss over several weeks, while a concerning symptom in a cancer patient, is not the most specific or immediate finding indicative of superior vena cava syndrome (SVCS). Weight loss is a general symptom of malignancy (cancer cachexia) due to increased metabolic demands, catabolism, and reduced caloric intake. SVCS involves specific obstruction of venous return to the heart, leading to distinct signs and symptoms related to impaired blood flow from the head, neck, and upper extremities.

Choice B rationale

Facial swelling and edema is the most concerning and classic finding indicative of superior vena cava syndrome. Obstruction of the superior vena cava, often by an extrinsic tumor compression (e.g., lung cancer, lymphoma), impairs venous drainage from the head, neck, and upper extremities. This leads to increased hydrostatic pressure in these areas, resulting in visible facial edema, periorbital edema, and swelling of the neck and arms.

Choice C rationale

Increased appetite is generally not associated with superior vena cava syndrome or advanced cancer. Patients with cancer, especially those with advanced disease or undergoing treatment, frequently experience anorexia, early satiety, and altered taste, leading to decreased appetite and weight loss. SVCS itself does not directly influence appetite regulation, though the underlying malignancy might contribute to systemic symptoms that affect appetite negatively.

Choice D rationale

Mild nausea and vomiting, while possible symptoms in a cancer patient due to various factors (e.g., chemotherapy, pain medication, hypercalcemia), are not specifically indicative of superior vena cava syndrome. SVCS is characterized by signs and symptoms related to venous congestion in the upper body. Nausea and vomiting are non-specific gastrointestinal symptoms and do not directly arise from the pathophysiology of superior vena cava obstruction.

Choice A rationale

Monitoring temperature is crucial for detecting infection, which is a risk for all chemotherapy patients, but it is not the highest priority specifically for thrombocytopenia. Thrombocytopenia's primary risk is bleeding, not infection, although infections can exacerbate bleeding.

Choice B rationale

Monitoring for pathological fractures is primarily associated with bone metastases or certain bone diseases, not directly with thrombocytopenia. While some cancers can affect bone integrity, thrombocytopenia itself does not increase the risk of pathological fractures.

Choice C rationale

Ambulation three times daily is a general mobility intervention. For a client with thrombocytopenia, ambulation could increase the risk of injury and subsequent bleeding, especially if the platelet count is critically low. Therefore, it would not be the highest priority and might even be contraindicated depending on the severity.

Choice D rationale

Thrombocytopenia is a condition characterized by a low platelet count, which impairs the body's ability to form clots and stop bleeding. Therefore, monitoring the platelet count provides direct quantitative information on the severity of the bleeding risk and guides interventions to prevent hemorrhage, making it the highest priority. Normal platelet count is 150,000 to 450,000 platelets per microliter of blood.